RemeGen Co., Ltd. (9995.HK)
Develops biological drugs for cancer, autoimmune diseases, and eye conditions in China and the US.
82.75-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+41.1%
The outlook
RemeGen (9995.HK) trades at 82.75 with analyst consensus leaning toward Buy. The stock sits in the lower third of its 52-week range, with a mixed near-term trend, while the average analyst price target implies roughly 41% upside from current levels. The trailing P/E of 55.5 reflects a premium valuation.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 15 analysts
Price trendMixed vs its moving averages
52-week range36% of the way from its 52-week low to high
Price targetAvg target +41% vs current price
Analyst price target
~12-month · 15 analysts116.29average target+40.5% vs now
Now 82.75
Low 76.52High 143.64
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$49.29B
52-wk high
126.60
52-wk low
57.65
50-day avg
78.69
200-day avg
86.81
Trailing P/E
55.5